[go: up one dir, main page]

NO20033673D0 - Fusjonsprotein for sekresjon av et protein av interesse til supernatanten til en bakteriekultur - Google Patents

Fusjonsprotein for sekresjon av et protein av interesse til supernatanten til en bakteriekultur

Info

Publication number
NO20033673D0
NO20033673D0 NO20033673A NO20033673A NO20033673D0 NO 20033673 D0 NO20033673 D0 NO 20033673D0 NO 20033673 A NO20033673 A NO 20033673A NO 20033673 A NO20033673 A NO 20033673A NO 20033673 D0 NO20033673 D0 NO 20033673D0
Authority
NO
Norway
Prior art keywords
protein
interest
supernatant
secretion
bacterial culture
Prior art date
Application number
NO20033673A
Other languages
English (en)
Other versions
NO331271B1 (no
NO20033673L (no
Inventor
Paul Habermann
Johann Ertl
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of NO20033673D0 publication Critical patent/NO20033673D0/no
Publication of NO20033673L publication Critical patent/NO20033673L/no
Publication of NO331271B1 publication Critical patent/NO331271B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/62Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81Protease inhibitors
    • C07K14/815Protease inhibitors from leeches, e.g. hirudin, eglin
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • C12N15/625DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/70Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Emergency Medicine (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Obesity (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20033673A 2001-02-20 2003-08-19 Fusjonsprotein for sekresjon av et protein av interesse til supernatanten til en bakteriekultur, fremgangsmate, plasmid og vertscelle for fremstilling NO331271B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10108212A DE10108212A1 (de) 2001-02-20 2001-02-20 Fusionsprotein zur Sekretion von Wertprotein in bakterielle Überstände
PCT/EP2002/001307 WO2002068660A1 (en) 2001-02-20 2002-02-08 Fusion protein for the secretion of a protein of interest into the supernatant of the bacterial culture

Publications (3)

Publication Number Publication Date
NO20033673D0 true NO20033673D0 (no) 2003-08-19
NO20033673L NO20033673L (no) 2003-10-17
NO331271B1 NO331271B1 (no) 2011-11-14

Family

ID=7674913

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20033673A NO331271B1 (no) 2001-02-20 2003-08-19 Fusjonsprotein for sekresjon av et protein av interesse til supernatanten til en bakteriekultur, fremgangsmate, plasmid og vertscelle for fremstilling

Country Status (18)

Country Link
EP (1) EP1364029B1 (no)
JP (1) JP4243104B2 (no)
KR (1) KR100858009B1 (no)
CN (1) CN100500853C (no)
AT (1) ATE314480T1 (no)
AU (1) AU2002231784B2 (no)
BR (1) BRPI0207394B8 (no)
CA (1) CA2438886C (no)
DE (2) DE10108212A1 (no)
DK (1) DK1364029T3 (no)
ES (1) ES2254658T3 (no)
IL (1) IL157414A0 (no)
MX (1) MXPA03007114A (no)
NO (1) NO331271B1 (no)
NZ (1) NZ527643A (no)
PE (1) PE20020876A1 (no)
WO (1) WO2002068660A1 (no)
ZA (1) ZA200305869B (no)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9453251B2 (en) 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
PL2327718T3 (pl) 2003-11-21 2016-10-31 Ulepszone systemy ekspresyjne z wykorzystaniem systemu sekrecji SEC
ES2663594T3 (es) 2004-01-16 2018-04-16 Pfenex Inc Expresión de proteínas de mamífero en Pseudomonas fluorescens
CA2574953A1 (en) 2004-07-26 2006-02-09 Dow Global Technolgies Inc. Process for improved protein expression by strain engineering
DE102006031955A1 (de) * 2006-07-11 2008-01-17 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von Insulinanaloga mit dibasischem B-Kettenende
DE102006031962A1 (de) 2006-07-11 2008-01-17 Sanofi-Aventis Deutschland Gmbh Amidiertes Insulin Glargin
DE102006050332A1 (de) 2006-10-25 2008-04-30 Wacker Chemie Ag DNS-Konstrukt und Verfahren zur fermentativen Herstellung von Fusionsproteinen
AU2008210538B2 (en) 2007-01-31 2013-06-06 Pelican Technology Holdings, Inc. Bacterial leader sequences for increased expression
JP5444553B2 (ja) 2007-04-27 2014-03-19 フェネックス インコーポレイテッド 微生物宿主を迅速にスクリーニングして、異種タンパク質発現の収率および/または質が改善されている特定の株を同定する方法
US9580719B2 (en) 2007-04-27 2017-02-28 Pfenex, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
KR20100111683A (ko) 2008-01-09 2010-10-15 사노피-아벤티스 도이칠란트 게엠베하 극히 지연된 시간-작용 프로필을 갖는 신규 인슐린 유도체
DE102008025007A1 (de) 2008-05-24 2009-11-26 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
DE102008003568A1 (de) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
DE102008025008A1 (de) 2008-05-24 2009-11-26 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
DE102008003566A1 (de) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
KR20100111682A (ko) 2008-01-09 2010-10-15 사노피-아벤티스 도이칠란트 게엠베하 극히 지연된 시간-작용 프로필을 갖는 신규 인슐린 유도체
US9018001B2 (en) 2008-10-02 2015-04-28 Unitargeting Research As Kit for the optimisation of protein synthesis/secretion
LT3228320T (lt) 2008-10-17 2020-03-10 Sanofi-Aventis Deutschland Gmbh Insulino ir glp-1 agonisto derinys
PE20121362A1 (es) 2009-11-13 2012-10-17 Sanofi Aventis Deutschland Composicion farmaceutica que comprende despro36exendina-4(1-39)-lys6-nh2, insulina gly(a21)-arg(b31)-arg(b32) y metionina
KR101772372B1 (ko) 2009-11-13 2017-08-29 사노피-아벤티스 도이칠란트 게엠베하 Glp-1 효능제 및 메티오닌을 포함하는 약제학적 조성물
EP2611458B1 (en) 2010-08-30 2016-09-21 Sanofi-Aventis Deutschland GmbH Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
AU2012300978B2 (en) 2011-08-29 2017-04-27 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
US11084860B2 (en) 2013-03-12 2021-08-10 The General Hospital Corporation Modified Mullerian inhibiting substance (MIS) proteins and uses thereof for the treatment of diseases
EP4008339A1 (en) 2013-12-11 2022-06-08 The General Hospital Corporation Use of mullerian inhibiting substance (mis) proteins for contraception
HRP20230470T1 (hr) 2014-12-12 2023-07-21 Sanofi-Aventis Deutschland Gmbh Formulacija fiksnog omjera inzulin glargin/liksisenatid
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第2型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第2型糖尿病病患之治療

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1341414C (fr) * 1984-03-27 2002-12-31 Paul Tolstoshev Vecteurs d'expression de l'hirudine, cellules transformees et procede de preparation de l'hirudine
GB8927722D0 (en) * 1989-12-07 1990-02-07 British Bio Technology Proteins and nucleic acids
EP0511393B1 (en) * 1990-11-08 1996-07-31 Japan Energy Corporation Hirudine mutant, production thereof, anticoagulant, secretory vector, microorganism transformed by said vector, and production of product from said microorganism
WO1995009125A1 (en) * 1992-09-28 1995-04-06 Pehr Harold T Kicker latch for container closures
DE10033195A1 (de) * 2000-07-07 2002-03-21 Aventis Pharma Gmbh Bifunktionale Fusionsproteine aus Hirudin und TAP

Also Published As

Publication number Publication date
EP1364029B1 (en) 2005-12-28
ATE314480T1 (de) 2006-01-15
AU2002231784B2 (en) 2006-10-26
BR0207394A (pt) 2004-02-10
PE20020876A1 (es) 2002-11-05
DE10108212A1 (de) 2002-08-22
EP1364029A1 (en) 2003-11-26
JP2004518444A (ja) 2004-06-24
DE60208343T2 (de) 2006-06-22
NO331271B1 (no) 2011-11-14
NO20033673L (no) 2003-10-17
NZ527643A (en) 2005-07-29
IL157414A0 (en) 2004-03-28
CA2438886A1 (en) 2002-09-06
BRPI0207394B8 (pt) 2021-05-25
JP4243104B2 (ja) 2009-03-25
WO2002068660A1 (en) 2002-09-06
KR20030074842A (ko) 2003-09-19
CA2438886C (en) 2013-07-23
MXPA03007114A (es) 2003-11-18
BRPI0207394B1 (pt) 2015-06-16
CN100500853C (zh) 2009-06-17
HK1065335A1 (zh) 2005-02-18
DK1364029T3 (da) 2006-05-08
CN1529757A (zh) 2004-09-15
ES2254658T3 (es) 2006-06-16
ZA200305869B (en) 2004-06-25
DE60208343D1 (de) 2006-02-02
KR100858009B1 (ko) 2008-09-11

Similar Documents

Publication Publication Date Title
NO20033673D0 (no) Fusjonsprotein for sekresjon av et protein av interesse til supernatanten til en bakteriekultur
ATE317441T1 (de) Cathepsin-02-protease
EP1451293A4 (en) NEW SULFURYLASE LUCIFERASE FUSION PROTEINS AND TEMPERATURE STABLE SULFURYLASE
DK1200479T3 (da) Multiple cytokin-antistof-komplekser
DK1088084T3 (da) Erythropoietin analog-humant serumalbumin fusionsprotein
EP1490094A4 (en) ANTIBODY FUSION PROTEINS AS EFFECTIVE ADJUVANTS FOR PROTEIN VACCINATION
AU4981101A (en) Subtilisin variants
WO2005021592A3 (en) Enhancing the circulating half-life of interleukin-2 proteins
WO2005003313A8 (en) Methods and compositions for enhanced protein expression and purification
HUP0301659A2 (hu) Kukorica cellulóz-szintetázok és alkalmazásuk
EP1470236A4 (en) PROCESSES AND COMPOSITIONS FOR PROTEIN EXPRESSION AND CLEANING
DE60232577D1 (de) Oligomerische komplexe von chimären proteinen mit verbessertem immunogenen potential
ATE457352T1 (de) Subtilisin-carlsberg-proteine mit verminderter immunogenität
ATE439441T1 (de) Veränderte, fluoreszierende proteine
WO2005017110A3 (en) Engineered proteases for affinity purification and processing of fusion proteins
MEP27908A (en) Signal sequences for the production of leu-hirudine via secretion by e. coli in a culture medium
ATE323763T1 (de) Dna & protein bindende miniatur proteine
AU2002349231A1 (en) Methylotrophic bacterium for the production of recombinant proteins and other products
YU69691A (sh) Postupak za pripremu stranih proteina u streptomicetama
AU2002214542A1 (en) Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof
AU2001238064A1 (en) 18477, a human protein kinase and uses therefor
WO2001004143A3 (en) Prostase vaccine
WO2002052270A3 (en) Method for identifying substances which positively influence inflammatory conditions of chronic inflammatory airway diseases
EP1451367A4 (en) GENE OF LEADING PEPTIDES FOR SECRETING RECOMBINANT PROTEINS IN BACTERIA
DK1002056T3 (da) ppGpp-syntease og ekspressionssystem til forbedret fremstilling af protein af interesse

Legal Events

Date Code Title Description
MK1K Patent expired